Sullivan, David

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civeira, F., Burgess, L., Langslet, G., Scott, R., Olsson, A. G., Sullivan, D., et al. (2015) · The Lancet

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 756

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

Stroes, E., Colquhoun, D., Sullivan, D., Civeira, F., Rosenson, R. S., Watts, G. F., Bruckert, E., Cho, L., Dent, R., Knusel, B., et al. (2014) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 526

Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients: The GAUSS Randomized Trial

Sullivan, D., Olsson, A. G., Scott, R., Kim, J. B., Xue, A., Gebski, V., Wasserman, S. M., & Stein, E. A. (2012) · JAMA

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 447

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

on behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J., et al. (2011) · Diabetologia

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 371

Triglyceride-lowering effect of marine polyunsaturates in patients with hypertriglyceridemia.

Sanders, T. A., Sullivan, D. R., Reeve, J., & Thompson, G. R. (1985) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc.

Fatty Acid Research and HealthLipid metabolism and disorders

Cited by 212

Omega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis

Kotwal, S., Jun, M., Sullivan, D., Perkovic, V., & Neal, B. (2012) · Circulation: Cardiovascular Quality and Outcomes

Fatty Acid Research and HealthNutritional Studies and Diet

Cited by 201

Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients: A Meta-Analysis

Boekholdt, S. M., Arsenault, B. J., Hovingh, G. K., Mora, S., Pedersen, T. R., LaRosa, J. C., Welch, K. M. A., Amarenco, P., DeMicco, D. A., Tonkin, A. M., et al. (2013) · Circulation

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 196

Indications for Omega-3 Long Chain Polyunsaturated Fatty Acid in the Prevention and Treatment of Cardiovascular Disease

Nestel, P., Clifton, P., Colquhoun, D., Noakes, M., Mori, T. A., Sullivan, D., & Thomas, B. (2015) · Heart, Lung and Circulation

Fatty Acid Research and HealthNutritional Studies and Diet

Cited by 160

Continuous Positive Airway Pressure Reduces Postprandial Lipidemia in Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Crossover Trial

Phillips, C. L., Yee, B. J., Marshall, N. S., Liu, P. Y., Sullivan, D. R., & Grunstein, R. R. (2011) · American Journal of Respiratory and Critical Care Medicine

Obstructive Sleep Apnea ResearchSleep and related disorders

Cited by 145

RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts

Watts, G. F., Schwabe, C., Scott, R., Gladding, P. A., Sullivan, D., Baker, J., Clifton, P., Hamilton, J., Given, B., Melquist, S., et al. (2023) · Nature Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 105

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes

on behalf of the FIELD study investigators, Taskinen, M.-R., Barter, P. J., Ehnholm, C., Sullivan, D. R., Mann, K., Simes, J., Best, J. D., Hamwood, S., & Keech, A. C. (2010) · Diabetologia

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 94

RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia

Gaudet, D., Clifton, P., Sullivan, D., Baker, J., Schwabe, C., Thackwray, S., Scott, R., Hamilton, J., Given, B., Melquist, S., et al. (2023) · NEJM Evidence

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 71

Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate

Taskinen, M.-R., Sullivan, D. R., Ehnholm, C., Whiting, M., Zannino, D., Simes, R. J., Keech, A. C., & Barter, P. J. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipoproteins and Cardiovascular HealthFolate and B Vitamins Research

Cited by 63

Apolipoprotein A-I-stimulated Apolipoprotein E Secretion from Human Macrophages Is Independent of Cholesterol Efflux

Kockx, M., Rye, K.-A., Gaus, K., Quinn, C. M., Wright, J., Sloane, T., Sviridov, D., Fu, Y., Sullivan, D., Burnett, J. R., et al. (2004) · Journal of Biological Chemistry

Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

Cited by 47

Clinical profile of statin intolerance in the phase 3 GAUSS-2 Study

Cho, L., Rocco, M., Colquhoun, D., Sullivan, D., Rosenson, R. S., Dent, R., Xue, A., Scott, R., Wasserman, S. M., & Stroes, E. (2016) · Cardiovascular Drugs and Therapy

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 30

PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer

Scheinberg, T., Lin, H.-M., Fitzpatrick, M., Azad, A. A., Bonnitcha, P., Davies, A., Heller, G., Huynh, K., Mak, B., Mahon, K., et al. (2024) · Prostate Cancer and Prostatic Diseases

Cancer, Lipids, and MetabolismProstate Cancer Treatment and Research

Cited by 15